 |
|
|
 |
|
|
|
|
| April 25, 2003 |
|
Review of the Mission of Mitsubishi Kagaku Institute of Life Sciences (MITILS)
and Invitation of Applications for Research Project Leaders |
|
Mitsubishi Chemical Corporation (Head office: Chiyoda-ku, Tokyo; President: Ryuichi Tomizawa) and Mitsubishi Kagaku Institute of Life Sciences (Head office: Chiyoda-ku; President: Yoshitaka Nagai) reviewed the mission of MITILS, in order to accelerate fundamental research that contributes to enhance better understanding of human diseases and advance medical treatments, which leads to strengthen health care business in Mitsubishi Chemical Group. As part of the review, we decided to invite applications for new research project leaders.
MITILS was established in 1971. Since then, MITILS has achieved a great number of scientific results as a pioneer in fundamental research of life sciences in Japan. In the wake of decoding of the human genome sequence, the current research in life sciences is rapidly heading into a post-genome age with particular spotlights on global understanding of functions of gene products challenged from new points of views such as proteomics and glycomics. As for these fields, MITILS has a great accumulation of knowledge and technology.
Meanwhile, Mitsubishi Chemical Group has defined health care business segment as one of the three pillars for sustainable growth of the Group in the mid-term management plan, "Kakushin Plan" started from April 2003. In order to reinforce and expand the business, thus, the Group clearly positioned MITILS as the core institute for fundamental research supporting life-science business, especially health care business of the Group.
Based on the above scheme, the research system and projects of MITILS will be reviewed. From here on, its research will be developed with a focus on "fundamental research that contributes to enhance better understanding of human diseases and advance medical treatments." Until today, MITILS has achieved excellent outcomes; for example, outstanding research results in the areas of Neuroscience, Developmental Biology, and Immunology. In addition, it succeeded unparalleled technological innovation in life sciences, such as unique life-science technologies for research infrastructure utilizing the most cutting-edge technologies for chemical synthesis of sugar chains and cell-free synthesis of various kinds of proteins introduced in post-genome age. MITILS expects that these accumulated technologies will be integrated with new vitality and results to be produced from April 2004. By aggressively pursuing fundamental research commitment that unveils molecular-level secrets of etiology and maladies in human, MITILS will aim for future discoveries in obtaining of targeted drug candidates and accelerating more advanced diagnostics and medical treatments.
Mitsubishi Chemical Corporation intends to continuously strengthen the position of MITILS as Center of Excellence. Furthermore, MITILS is going to make a social contribution in the field of life sciences through health care business of the Group, while pursuing original and significant achievements with new research project leaders who will join us from April 2004.
For the details of application, please visit http://www.mitils.co.jp
| For further information, please contact |
| Public Relations and Investor Relations Dept., |
| Mitsubishi Chemical Corporation |
| Tel: [+81]-(0)3-3283-6274 |
|
|
|
<Reference>
Mitsubishi Kagaku Institute of Life Sciences invites applications for research project leaders who wish to take the initiative in research projects that commence in 2004 as follows:
| 1. |
Duration of application: May 1 through June 30, 2003 |
| 2. |
Focused research area:
| 1) |
Mental health: studies on elucidation of mechanisms of functions and dysfunction of cerebral/neurological activities to shed a new light on psychiatric and neurological disorders, such as Alzheimer's disease, schizophrenia, depression, and mental retardation |
| 2) |
Physical health: studies on elucidation of mechanisms of functions and dysfunction of cardiovascular and metabolic systems to overcome disorders observed in tissues and organs involved in these systems, such as cerebral infarction, myocardial infarction, arteriosclerosis, and diabetes |
| 3) |
Technological innovation: studies on development of epochal technologies in life-science research, e.g. structural and functional analyses of disease-related glycoproteins and membrane proteins, and analysis of genomic functions and genetic manipulation for unveiling disease mechanisms |
|
| 3. |
Number of research project leaders to be selected: About 10 applicants |
| 4. |
Research project formation:
| 1) |
A research team under a research project leader, or |
| 2) |
Research teams with sub-leaders under a research project leader |
|
| 5. |
Annual research budget:
Between 50 and 200 million yen/research (including costs for personnel, consumable items, and apparatus for research, etc.) |
| 6. |
Evaluation:
The review board will evaluate applications and select potential research project leaders through the subsequent interviews. |
| 7. |
Patents:
Intellectual property rights will belong to MCC. (The incentive grants system will be provided. The details will be explained at the interview.) |
| 8. |
Duration of research: A 5-year tenure system |
| 9. |
Commencement of research: April 1, 2004 |
| 10. |
Submission of application forms:
A set of application forms can be downloaded from the website of MITILS (http://www.mitils.co.jp). Applicants should fill out the complete forms and mail them with an envelope written as "APPLICATION FORM" in red to the following address: |
Admission Office
Mitsubishi Kagaku Institute of Life Sciences
11 Minamiooya, Machida, Tokyo 194-8511, Japan |
|
|
|
 |
|
|
|
